{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:38:16Z","timestamp":1792453096060,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00277-018-3540-1","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T13:00:25Z","timestamp":1541768425000},"page":"401-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Se-Il","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ree","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"3540_CR1","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato PE (2016) Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 5:e200","journal-title":"Oncogenesis"},{"issue":"5","key":"3540_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1477-2574.2010.00178.x","volume":"12","author":"KC Fearon","year":"2010","unstructured":"Fearon KC, Baracos VE (2010) Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford) 12(5):323\u2013324","journal-title":"HPB (Oxford)"},{"issue":"2","key":"3540_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","volume":"4","author":"VC Vaughan","year":"2013","unstructured":"Vaughan VC, Martin P, Lewandowski PA (2013) Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 4(2):95\u2013109","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"3540_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/00016489.2016.1277263","volume":"137","author":"H Orell-Kotikangas","year":"2017","unstructured":"Orell-Kotikangas H, Osterlund P, Makitie O, Saarilahti K, Ravasco P, Schwab U, Makitie AA (2017) Cachexia at diagnosis is associated with poor survival in head and neck cancer patients. Acta Otolaryngol 137(7):778\u2013785","journal-title":"Acta Otolaryngol"},{"issue":"5","key":"3540_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495","journal-title":"Lancet Oncol"},{"issue":"11","key":"3540_CR6","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00520-016-3287-y","volume":"24","author":"D Srdic","year":"2016","unstructured":"Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M (2016) Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer 24(11):4495\u20134502","journal-title":"Support Care Cancer"},{"issue":"5","key":"3540_CR7","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.clnu.2016.09.008","volume":"36","author":"AAL Vigano","year":"2017","unstructured":"Vigano AAL, Morais JA, Ciutto L, Rosenthall L, di Tomasso J, Khan S, Olders H, Borod M, Kilgour RD (2017) Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients. Clin Nutr 36(5):1378\u20131390","journal-title":"Clin Nutr"},{"issue":"18","key":"3540_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.clinbiochem.2017.07.011","volume":"50","author":"A Loumaye","year":"2017","unstructured":"Loumaye A, Thissen JP (2017) Biomarkers of cancer cachexia. Clin Biochem 50(18):1281\u20131288","journal-title":"Clin Biochem"},{"issue":"2","key":"3540_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13539-011-0027-5","volume":"2","author":"JM Argiles","year":"2011","unstructured":"Argiles JM, Lopez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S (2011) The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2(2):87\u201393","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"3540_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","volume":"40","author":"E Douglas","year":"2014","unstructured":"Douglas E, McMillan DC (2014) Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev 40(6):685\u2013691","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"3540_CR11","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85(9):1001\u20131005","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"9","key":"3540_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 90(9):790\u2013795","journal-title":"Am J Hematol"},{"issue":"4","key":"3540_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"5","key":"3540_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial G (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"5","key":"3540_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857\u20131861","journal-title":"Blood"},{"issue":"6","key":"3540_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842","journal-title":"Blood"},{"issue":"4","key":"3540_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hon.2233","volume":"34","author":"O Bairey","year":"2016","unstructured":"Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R (2016) Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 34(4):184\u2013192","journal-title":"Hematol Oncol"},{"issue":"1","key":"3540_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/bjc.2014.277","volume":"111","author":"KT Troppan","year":"2014","unstructured":"Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M (2014) C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 111(1):55\u201360","journal-title":"Br J Cancer"},{"issue":"4","key":"3540_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13277-012-0337-z","volume":"33","author":"Y Cao","year":"2012","unstructured":"Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, Qiu MZ, Cai XY, Jin Y, Sun YL, Jiang WQ (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 33(4):1039\u20131044","journal-title":"Tumour Biol"},{"issue":"26","key":"3540_CR20","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.2011.39.2100","volume":"30","author":"KR Carson","year":"2012","unstructured":"Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA (2012) Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 30(26):3217\u20133222","journal-title":"J Clin Oncol"},{"issue":"1","key":"3540_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/annonc\/mdt481","volume":"25","author":"L Weiss","year":"2014","unstructured":"Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A (2014) Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 25(1):171\u2013176","journal-title":"Ann Oncol"},{"issue":"5","key":"3540_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.13026","volume":"167","author":"A Ganti","year":"2014","unstructured":"Ganti A, Liu W, Luo S, Sanfilippo KM, Roop R, Lynch R, Riedell P, O'Brian K, Colditz GA, Carson KR (2014) Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol 167(5):699\u2013702","journal-title":"Br J Haematol"},{"issue":"10","key":"3540_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00277-015-2438-4","volume":"94","author":"HS Hwang","year":"2015","unstructured":"Hwang HS, Yoon DH, Suh C, Huh J (2015) Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. Ann Hematol 94(10):1655\u20131665","journal-title":"Ann Hematol"},{"issue":"7","key":"3540_CR24","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1080\/10428194.2016.1257793","volume":"58","author":"T Li","year":"2017","unstructured":"Li T, Liu ZG, Liang PQ, Wang HT (2017) Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China. Leuk Lymphoma 58(7):1624\u20131629","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"3540_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/ajh.24465","volume":"91","author":"DY Xiao","year":"2016","unstructured":"Xiao DY, Luo S, O'Brian K, Ganti A, Riedell P, Sanfilippo KM, Lynch RC, Liu W, Carson KR (2016) Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol 91(10):1002\u20131007","journal-title":"Am J Hematol"},{"issue":"5","key":"3540_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/jcsm.12115","volume":"7","author":"SI Go","year":"2016","unstructured":"Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, Kim Y, Kim RB, Lee SI, Lee GW (2016) Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle 7(5):567\u2013576","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"29","key":"3540_CR27","doi-asserted-by":"publisher","first-page":"47007","DOI":"10.18632\/oncotarget.16552","volume":"8","author":"SI Go","year":"2017","unstructured":"Go SI, Park MJ, Song HN, Kim HG, Kang MH, Kang JH, Kim HR, Lee GW (2017) A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget 8(29):47007\u201347019","journal-title":"Oncotarget"},{"issue":"12","key":"3540_CR28","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-015-2499-4","volume":"94","author":"N Nakamura","year":"2015","unstructured":"Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, Kito Y, Kitagawa J, Kanemura N, Goto N, Shiraki M, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H (2015) Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol 94(12):2043\u20132053","journal-title":"Ann Hematol"},{"issue":"4","key":"3540_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12185-016-2052-9","volume":"104","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Wei Y, Huang F, Wei X, Wei Q, Hao X, Zhang Y, Feng R (2016) Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 104(4):485\u2013490","journal-title":"Int J Hematol"},{"issue":"1","key":"3540_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"9403","key":"3540_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157\u2013163","journal-title":"Lancet"},{"issue":"5","key":"3540_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"7","key":"3540_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629\u2013635","journal-title":"Lancet Oncol"},{"issue":"8","key":"3540_CR34","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26(8):1364\u20131370","journal-title":"J Clin Oncol"},{"issue":"1","key":"3540_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-016-2819-3","volume":"96","author":"Y Ochi","year":"2017","unstructured":"Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N, Matsushita A, Imai Y, Hashimoto H, Ishikawa T (2017) Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 96(1):1\u20138","journal-title":"Ann Hematol"},{"issue":"6","key":"3540_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1634\/theoncologist.2017-0361","volume":"23","author":"H Liu","year":"2018","unstructured":"Liu H, Zhang CL, Feng R, Li JT, Tian Y, Wang T (2018) Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma: an effective tool for comprehensive geriatric assessment. Oncologist 23(6):722\u2013729","journal-title":"Oncologist"},{"issue":"2","key":"3540_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12185-011-0993-6","volume":"95","author":"J Feng","year":"2012","unstructured":"Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y (2012) Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol 95(2):143\u2013148","journal-title":"Int J Hematol"},{"issue":"11","key":"3540_CR38","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.leukres.2014.09.006","volume":"38","author":"X Han","year":"2014","unstructured":"Han X, Wang J, Zhang N, Yao J, Feng Y, Li D, Liu P, Yang J, Zhou S, Qin Y, Yang S, Gui L, He X, Shi Y (2014) The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. Leuk Res 38(11):1291\u20131298","journal-title":"Leuk Res"},{"issue":"2","key":"3540_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.24223","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Jais JP, Ghesquieres H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91(2):179\u2013184","journal-title":"Am J Hematol"},{"issue":"2","key":"3540_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1017\/S0029665115004279","volume":"75","author":"CM Prado","year":"2016","unstructured":"Prado CM, Cushen SJ, Orsso CE, Ryan AM (2016) Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc 75(2):188\u2013198","journal-title":"Proc Nutr Soc"},{"issue":"8","key":"3540_CR41","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920\u20132926","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3540_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","volume":"41","author":"BH Tan","year":"2015","unstructured":"Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA (2015) Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol 41(3):333\u2013338","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3540-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:11:41Z","timestamp":1573240301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3540"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3540-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is a retrospective analysis without any intervention and thus did not require informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}